At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

But the report, on the experiences of 13 patients, found that the drug had no benefit for some people and that some who ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long COVID when administered outside of an infection. Administration of Paxlovid ...

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer PFE.N COVID-19 treatment Paxlovid, Bristol Myers Squibb's BMY.N cancer cell therapies and vaccines ...

11,358,953 in the manufacture, use, and sale of Paxlovid. The company said that in a ruling over a summary judgment motion filed by Pfizer (PFE), the court determined that its ‘953 patent was ...

Get Wall Street's Hottest Chart Every Morning A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's PFE Paxlovid (nirmatrelvir / ritonavir ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Valued at a market cap of $152.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company dedicated to advancing ...

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, ...